ALSO NOTED: New River inks new licensing deal; Panacea nails $7M round; Miravant CEO resigns; and much more...

> New River Pharmaceuticals has entered into a licensing deal with the Ernest Gallo Clinic and Research Center at the University of California San Francisco to investigate a new approach toward improving the use of opioid analgesics in the treatment of pain by reducing the development of tolerance. Release

> Panacea Pharmaceuticals of Gaithersburg, Maryland, has raised $7 million in its third round. Mitsubishi Corporation Life Sciences Venture, Olympus, JSR, Shin-Etsu Chemical, Fuji Photo Film, Dai Nippon Printing, and Tokio Marine & Nichido Fire Insurance all participated. Release 

> Dutch biotech Pepscan Systems has raised $6 million in its first round. Release

> Chutes & Ladders: Gary S. Kledzik, PhD, CEO, chairman and director of Miravant Medical Technologies of Santa Barabra, California, has resigned. Release

> A new study from researchers at Columbia University says that prescription drug abuse in the US has hit epidemic proportions, with more than 15 million people -- including 2.3 million teenagers -- abusing pharmaceuticals. Story

And Finally... New York City health officials plan to monitor how well diabetics manage their ailment. Story

Suggested Articles

Sarepta will negotiate a warning for golodirsen rather than carry out more studies. But the implications of the rejection range beyond golodirsen.

The Pfizer Foundation has awarded 20 grants to organizations involved in tackling infectious diseases in low- and middle-income countries.

The engineered stain of E. coli performed no better than placebo, leading Synlogic to conclude its money is better spent on other assets.